Tekla Capital Management

Tekla Capital Management

A venture capital firm in Boston that focuses on securities of public and private healthcare companies.

Tekla Capital Management is a venture capital firm in Boston that focuses on securities of public and private healthcare companies. Founded 1986 in Boston, Massachusetts, United States, this venture capital invests in early stage ventures and late stage ventures. Its portfolio companies include VectivBio, Arkuda Therapeutics, Amphivena Therapeutics, Oculis, Milestone Pharmaceuticals, CuraSen Therapeutics, Galera Therapeutics, Atreca, Therachon, and Sutro Biopharma. As of February 2020, Tekla Capital Management has made 26 investments. Their most recent investment was on January 8, 2020, when VectivBio raised $35M. Tekla Capital Management has had 14 exits, the most notable of which include Atreca, CytomX Therapeutics, and Sutro Biopharma.

Timeline

Funded Companies

Company
Description
Website
Industry
Location
9 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Robert Benson

Senior Analyst, Research

Alan Kwan

Vice President, Research

Ashton Wilson

Senior Vice President

Christian Richard

Senior Vice President, Research

Christopher Abbott

Vice President

Daniel Omstead

President and CEO

Henry Skinner

Senior Vice President, Venture

Jason Akus

Senior Vice President, Research

Laura Woodward

Chief Compliance Officer and Vice President of Fund Administration

Loretta Tse

Senior Analyst

Peter Savitscus

Head Trader

Richard Goss

Senior Analyst, Research

Timothy Gasperoni

Senior Vice President, Research

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Amphivena Therapeutics

Arkuda Therapeutics

Atreca

CuraSen Therapeutics

Galera Therapeutics

Milestone Pharmaceuticals

Oculis

Sutro Biopharma

Therachon

VectivBio

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.